Moderna Inc
MRNA27.350USD
+0.130+0.48%
Trading geöffnet （ET）Kurse um 15 Minuten verzögert
10.56BMarktkapitalisierung
VerlustKGV TTM
mehr Informationen über Moderna Inc Unternehmen
Moderna, Inc. is a biotechnology company. The Company is advancing a new class of medicines made of messenger ribonucleic acid (mRNA). It is developing therapeutics and vaccines for infectious diseases, immuno-oncology, rare diseases and autoimmune diseases. mRNA medicines are designed to direct the body’s cells to produce intracellular, membrane or secreted proteins that have a therapeutic or preventive benefit with the potential to address a spectrum of diseases. The Company’s diverse development pipeline consists of 44 therapeutic and vaccine programs, 11 of which are in late-stage development. Its commercial products include Spikevax (its COVID vaccine) and mRESVIA (its respiratory syncytial virus (RSV) vaccine). Additionally, it has achieved four positive Phase III data readouts for its COVID vaccine (mRNA-1283), its RSV vaccine for high-risk adults aged 18 to 59 (mRNA-1345), its seasonal flu+COVID vaccine (mRNA-1083), and its seasonal flu vaccine (mRNA-1010).
Unternehmensinformationen
Unternehmens-codeMRNA
Name des UnternehmensModerna Inc
IPO-datumDec 07, 2018
Gegründet am2016
CEOMr. Stephane Bancel
Anzahl der mitarbeiter5800
WertpapierartOrdinary Share
GeschäftsjahresendeDec 07
Addresse325 Binney Street
StadtCAMBRIDGE
BörseNASDAQ Global Select Consolidated
LandUnited States of America
Postleitzahl02142
Telefon16177146500
Websitehttps://www.modernatx.com/
Unternehmens-codeMRNA
IPO-datumDec 07, 2018
Gegründet am2016
Führungskräfte
Name
Name/Position
Position
Aktienbesitz
Veränderung
Dr. Stephen Hoge, M.D.
Dr. Stephen Hoge, M.D.
President
President
1.61M
--
Mr. Paul Sagan
Mr. Paul Sagan
Independent Director
Independent Director
494.13K
+6.84%
Ms. Shannon Thyme Klinger
Ms. Shannon Thyme Klinger
Corporate Secretary, Chief Legal Officer
Corporate Secretary, Chief Legal Officer
25.61K
+8.78%
Mr. James M. Mock
Mr. James M. Mock
Chief Financial Officer
Chief Financial Officer
15.62K
+5.04%
Dr. Elizabeth G. (Betsy) Nabel, M.D.
Dr. Elizabeth G. (Betsy) Nabel, M.D.
Independent Director
Independent Director
2.10K
--
Tallett (Elizabeth E)
Tallett (Elizabeth E)
Independent Director
Independent Director
703.00
--
Mr. Noubar Afeyan ,
Mr. Noubar Afeyan ,
Non-Executive Independent Chairman of the Board, Co-Founder
Non-Executive Independent Chairman of the Board, Co-Founder
--
--
Dr. Rose Loughlin
Dr. Rose Loughlin
Executive Vice President - Research
Executive Vice President - Research
--
--
Mr. Jerh Collins
Mr. Jerh Collins
Chief Technical Operations and Quality Officer
Chief Technical Operations and Quality Officer
--
--
Mr. Stephane Bancel
Mr. Stephane Bancel
Chief Executive Officer, Director
Chief Executive Officer, Director
--
--
Mehr Anzeigen
Name
Name/Position
Position
Aktienbesitz
Veränderung
Dr. Stephen Hoge, M.D.
Dr. Stephen Hoge, M.D.
President
President
1.61M
--
Mr. Paul Sagan
Mr. Paul Sagan
Independent Director
Independent Director
494.13K
+6.84%
Ms. Shannon Thyme Klinger
Ms. Shannon Thyme Klinger
Corporate Secretary, Chief Legal Officer
Corporate Secretary, Chief Legal Officer
25.61K
+8.78%
Mr. James M. Mock
Mr. James M. Mock
Chief Financial Officer
Chief Financial Officer
15.62K
+5.04%
Dr. Elizabeth G. (Betsy) Nabel, M.D.
Dr. Elizabeth G. (Betsy) Nabel, M.D.
Independent Director
Independent Director
2.10K
--
Tallett (Elizabeth E)
Tallett (Elizabeth E)
Independent Director
Independent Director
703.00
--
Umsatzaufteilung
Währung: USDUpdate-Zeit: Sun, Apr 6
Währung: USDUpdate-Zeit: Sun, Apr 6
FY2024
FY2024Q4
FY2024Q3
FY2024Q2
FY2024Q1
FY2023
FY2023Q4
FY2023Q3
FY2023Q2
FY2023Q1
FY2022
FY2022Q4
FY2022Q3
FY2022Q2
FY2022Q1
FY2021
FY2020
Nach GeschäftsbereichUSD
Name
Umsatz
Anteil
COVID
3.08B
99.20%
RSV
25.00M
0.80%
Nach RegionUSD
Name
Umsatz
Anteil
United States
1.78B
57.41%
Rest of the World
853.00M
27.44%
Europe
598.00M
19.23%
Nach Geschäftsbereich
Nach Region
Nach GeschäftsbereichUSD
Name
Umsatz
Anteil
COVID
3.08B
99.20%
RSV
25.00M
0.80%
Aktionäre
Update-Zeit: Thu, Mar 13
Update-Zeit: Thu, Mar 13
Aktionärsstatistik
Art
Aktionärsstatistik
Aktionäre
Anteil
The Vanguard Group, Inc.
10.39%
Baillie Gifford & Co.
10.06%
Fidelity Management & Research Company LLC
4.75%
BlackRock Institutional Trust Company, N.A.
4.67%
State Street Global Advisors (US)
4.55%
Other
65.58%
Aktionärsstatistik
Aktionäre
Anteil
The Vanguard Group, Inc.
10.39%
Baillie Gifford & Co.
10.06%
Fidelity Management & Research Company LLC
4.75%
BlackRock Institutional Trust Company, N.A.
4.67%
State Street Global Advisors (US)
4.55%
Other
65.58%
Art
Aktionäre
Anteil
Investment Advisor
34.33%
Investment Advisor/Hedge Fund
25.19%
Corporation
4.68%
Hedge Fund
4.51%
Research Firm
3.25%
Individual Investor
2.56%
Bank and Trust
1.73%
Pension Fund
1.55%
Venture Capital
1.20%
Other
21.01%
Institutionelle Beteiligung
Update-Zeit: Mon, Jan 20
Update-Zeit: Mon, Jan 20
Berichtszeitraum
Anzahl der Institutionen
Gehaltenen Aktien
Anteil
Veränderung
2025Q1
2064
320.55M
82.92%
-6.59M
2024Q4
2176
321.41M
83.21%
-6.67M
2024Q3
2154
311.92M
81.18%
-17.40M
2024Q2
2186
316.03M
82.47%
-13.47M
2024Q1
2203
318.24M
83.12%
-1.14M
2023Q4
2309
311.40M
81.63%
+3.41M
2023Q3
2445
301.25M
79.05%
-6.86M
2023Q2
2461
301.15M
78.90%
-7.01M
2023Q1
2466
303.08M
78.58%
-1.88M
2022Q4
2442
300.08M
77.99%
-2.96M
Mehr Anzeigen
Aktionärsaktivitäten
Name
Gehaltenen Aktien
Anteil
Veränderung
Änderung%
Datum
The Vanguard Group, Inc.
40.18M
10.39%
+101.25K
+0.25%
Dec 31, 2024
Baillie Gifford & Co.
38.89M
10.06%
-3.57M
-8.40%
Dec 31, 2024
Fidelity Management & Research Company LLC
18.38M
4.75%
+1.28M
+7.51%
Dec 31, 2024
BlackRock Institutional Trust Company, N.A.
18.04M
4.67%
+471.49K
+2.68%
Dec 31, 2024
State Street Global Advisors (US)
17.58M
4.55%
+730.02K
+4.33%
Dec 31, 2024
Boston Biotech Ventures, L.L.C.
9.21M
2.38%
+160.31K
+1.77%
Mar 05, 2025
Theleme Partners LLP
7.31M
1.89%
+80.00K
+1.11%
Dec 31, 2024
Geode Capital Management, L.L.C.
7.24M
1.87%
+171.77K
+2.43%
Dec 31, 2024
OCHA, L.L.C.
6.56M
1.7%
--
--
Mar 05, 2025
Bancel (Stephane J)
5.49M
1.42%
--
--
Mar 05, 2025
Mehr Anzeigen
Verbundene ETFs
Update-Zeit: Sun, Apr 6
Update-Zeit: Sun, Apr 6
Name
Anteil
iShares Genomics Immunology and Healthcare ETF
3.1%
Global X Genomics & Biotechnology ETF
2.71%
Clough Select Equity ETF
2.62%
First Trust NYSE Arca Biotechnology Index Fund
2.28%
VanEck Biotech ETF
2.05%
SPDR S&P Biotech ETF
1.82%
Langar Global HealthTech ETF
1.81%
Virtus LifeSci Biotech Products ETF
1.17%
ROBO Global Healthcare Technology & Innovation ETF
1.16%
Direxion Daily S&P Biotech Bull 3X Shares
1.15%
Mehr Anzeigen
iShares Genomics Immunology and Healthcare ETF
Anteil3.1%
Global X Genomics & Biotechnology ETF
Anteil2.71%
Clough Select Equity ETF
Anteil2.62%
First Trust NYSE Arca Biotechnology Index Fund
Anteil2.28%
VanEck Biotech ETF
Anteil2.05%
SPDR S&P Biotech ETF
Anteil1.82%
Langar Global HealthTech ETF
Anteil1.81%
Virtus LifeSci Biotech Products ETF
Anteil1.17%
ROBO Global Healthcare Technology & Innovation ETF
Anteil1.16%
Direxion Daily S&P Biotech Bull 3X Shares
Anteil1.15%
Dividende
In den vergangenen 5 Jahren wurden insgesamt
0.00
USD an Dividenden ausgeschüttet.
Datum
Dividende
Stichtag für die Aktienregistrierung
Zahltag
Ex-Dividendentag
Keine Daten
Aktien-Split
Datum
Art
Verhältnis
Keine Daten
Datum
Art
Verhältnis
Keine Daten